Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976059 | 0.91 | HRH3 (0.37) | HRH3MCHR1TLR7ALDH1A1EPAS1 | |
| SCHEMBL13202986 | 0.91 | HRH3 (0.36) | HRH3MCHR1HTR1ADRD2HTR2A | |
| SCHEMBL2967168 | 0.82 | GHSR (0.38) | SLC2A1L3MBTL1ALDH1A1EPAS1 | |
| SCHEMBL2977932 | 0.79 | EPAS1 (0.45) | EPAS1 | |
| SCHEMBL2978235 | 0.78 | EPAS1 (0.41) | HRH3MCHR1EPAS1 | |
| SCHEMBL2970654 | 0.77 | TLR7 (0.48) | MEN1KMT2AKDM4ETLR7ALDH1A1 | |
| SCHEMBL2973398 | 0.77 | CTSS (0.42) | ALDH1A1EPAS1 | |
| SCHEMBL2962354 | 0.77 | EPAS1 (0.41) | TLR7EPAS1 | |
| SCHEMBL2965339 | 0.76 | MAPT (0.44) | MEN1KMT2AHTR1AHTR2ATLR7 | |
| SCHEMBL2970120 | 0.76 | KDM4E (0.43) | MEN1KMT2AL3MBTL1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | MEN1 4684/4885KMT2A 2900/4885SLC2A1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.